Last month the Center for Medicare & Medicaid Services (CMS) released open data on Medicare Plan D. This led me to ask the question, “What are the top monthly prescribed drugs in America, how much are individual patients and Medicare paying for these drugs, and what role can technology play in bringing down these costs?” These are some of the questions Americans face when paying for and managing their medications.
Thanks to this data and my analysis we can get a better picture of the market:
In the last 5 years, medication spending has risen substantially. The largest amount of spending by Medicare Part D for the top 10 monthly prescribed drugs went to Lantus (Insulin). In 2011, Medicare spent approximately $1.5 billion and ended in 2015 with $4.4 billion.
The drug that had the lowest amount of spending was Vyvanse. Spending was approximate $9 million in 2011 and by 2015 went up to an estimated $34 million. The spending for this drug increased by approximately 1.4% in sales each year following.
The cost of the top 10 monthly prescribed drugs continues to rise each year. If you look at the purple bars you can see that in 2015 the most expensive drug was Lantus (insulin), but on average the drug that cost the most was Januvia. It cost $1,974 annually for Medicare, which is about $164 per month. If we look at the shortest bars we can see Synthroid and Ventolin were in the running for least costly. The lowest average cost of a drug over the last 5 years was Ventolin HFA which was $122 average.
Imagine if you were a patient with a certain percent of your drug covered by Medicare. It might be a shocker that your drug that in 2011 cost $95 a month now has shot up to $217 a month in 2015. Especially if you have to pay out of pocket. The cost of Lantus (Insulin) is growing by an average of 23% each year. The rising cost is an added burden for patients who are diabetic because according to Diebetes.org they are already projected to spend up to $13,700 on medical expenditures.
Finding the Least Expensive Prescription Drugs
To make sense of the state of prescription drugs, I asked Dr. Ali Khoshnevis, Chief Health Officer at Tesser Health for his thoughts. Dr. Khoshnevis is an Optometrist and in 2011 co-founded the app WeRx.org to help people compare their prescription prices. The app has proven stories of impacting patients lives.
When asked about the cost of prescription drugs his thoughts were,
“I believe the most pressing concern regarding medications is the dramatically rising costs. Take insulin, between 2002 to 2013, the cost of insulin has tripled from $231 to $736 a year per patient. This is staggering considering insulin is a decade old life-saving medication.”
In our observations, Insulin did rise in costs for Medicare in 2013 the cost per user was $1,679 what Dr. Khoshnevis mentioned was the out-of-pocket cost patients have to pay. Why is this happening? According to DiabetesForecast.org, this is happening because drug prices are not regulated. In addition, lack of competition means drug companies can set the price of drugs.
Can Technology Help Reduce Out-of-Pocket Costs? What about Overall Medicare Spending?
In the chart above we use Medicare’s 2017 coverage gap to illustrate the out of pocket cost that a person would pay and applied it to the cost of Insulin over 2011-2015. For Medicare users, once you and your plan spend over $3,700 you will be in the gap. Beyond that, you will have to pay 40% of the cost for brand-name prescription drugs and 51% of the cost for generic drugs. Software that aggregates prescription data and shows it in a simple interface for users to compare prescription prices can help patients save money.
Some apps designed for everyone to do free drug price comparison are:
This is useful for drugs that have generic versions which tend to be cheaper, but some drugs like Insulin don’t have a generic. Based on the average growth in spending on Insulin by Medicare I project that it will cost over $3,984 this year. This means that as a user you will be in the coverage gap and have to pay 40% of the cost. So can software reduce Medicare spending? Here is what Dr. Khoshnevis had to say,
“We can reduce costs but it cannot fully eliminate the problem. The answer to Medicare’s problem is one that requires legislation that allows the government to negotiate drug prices. Unfortunately, I’m not sure that will happen anytime soon.” -Dr. Ali Khoshnevis
What we can learn from this analysis is that while Medicare may subsidize some of the payments there is still a heavy burden on the average American to afford prescription drugs. Software is enabling people to compare costs and has the potential to help medicare reduce spending. Because drug costs are not regulated the cost of life-saving drugs like Insulin will continue to rise leaving diabetic patients in a tough position when affording medication. I anticipate that as the cost of drugs continue to rise companies that design software to serve people and organizations will become more important in the discussion of drug price regulation.
*Email me at G@Linkedin.Miami for a copy of the data used in this analysis.
Feel free to comment, like, or share this if you found this insightful. Subscribe to get these data-driven essays in your inbox.4